The Valens Company Completes Final Step in Rebrand

KELOWNA, BC, June 22, 2020 /CNW/ – The Valens Company Inc. (formerly Valens GroWorks Corp.) (TSX: VLNS) (OTCQX: VLNCF) (the “Company” or “The Valens Company“), a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products, today announced that it has completed its continuance out of British Columbia and its incorporation under the Canada Business Corporations Act as “The Valens Company Inc.”

The common shares of the Company will begin trading under the Company’s new name on the Toronto Stock Exchange (the “TSX“) on June 24, 2020, marking the completion of its previously announced rebranding to “The Valens Company”.  All of the stock symbols for the Company’s securities will remain the same (i.e. “VLNS” and “VLNS.WT” for the Company’s shares and warrants, respectively on the TSX and “VLNCF” for the Company’s common shares on the OTCQX).  The new CUSIP numbers assigned to the Company’s common shares and warrants are 91914P108 and 91914P124 respectively. No further action is required to be taken by shareholders of the Company in connection with the continuance and name change.

“Since announcing our rebrand at the end of 2019, we have been working tirelessly to bring on new partners and launch innovative product lines and brands poised to dominate the oil-based market in Canada. As we continue to expand and diversify our platform, we look to further demonstrate to the market that we are positioned for long-term global success with our bespoke cannabinoid-based product development and manufacturing capabilities. Moving forward, we are eager to bring the Valens advantage to new customers, consumers and markets as we expect to unlock opportunities for growth at home and abroad,” said Tyler Robson, CEO of The Valens Company.

About The Valens Company

The Valens Company is a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products. The Valens Company is focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and product development and custom manufacturing.  Valens is the largest third-party extraction company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant.  The Valens Company currently offers a wide range of product formats, including tinctures, two-piece caps, soft gels, oral sprays and vape pens as well as beverages, concentrates, topicals, edibles, injectables, natural health products and has a strong pipeline of next-generation products in development for future release.  Finally, The Valens Company’s wholly-owned subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science.  For more information, please visit http://thevalenscompany.com.  The Valens Company’s investor deck can be found specifically at http://thevalenscompany.com/investors/.  

Notice regarding Forward Looking Statements

All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, economic conditions and anticipated courses of action.

The risks and uncertainties that may affect forward-looking statements include, among others,  regulatory risk, United States border crossing and travel bans, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, reliance on a single facility, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management’s current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.

SOURCE The Valens Company

For further information: Jeff Fallows, The Valens Company, Investor Relations, [email protected], +1.647.956.8254; KCSA Strategic Communications, Phil Carlson / Elizabeth Barker, [email protected], +1.212.896.1233 / +1.212.896.1203; Media, KCSA Strategic Communications, Anne Donohoe, [email protected], +1.212.896.1265

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.